Taysha Gene Therapies annual shares outstanding
2019
2020
2021
2022
2023
2024
2025
Taysha Gene Therapies Shares Outstanding History (TSHA)
Taysha Gene Therapies reported 285.1M shares outstanding at the end of fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 285.1M | 80.1M | +39.09% |
| 2024 | 2024-12-31 | 204.9M | 18.0M | +9.62% |
| 2023 | 2023-12-31 | 187.0M | 123.8M | +195.79% |
| 2022 | 2022-12-31 | 63.2M | 24.7M | +64.29% |
| 2021 | 2021-12-31 | 38.5M | 712,510 | +1.89% |
| 2020 | 2020-12-31 | 37.8M | 26.9M | +246.59% |
| 2019 | 2019-12-31 | 10.9M | — | — |
Taysha Gene Therapies quarterly shares outstanding
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 325.3M | 52.6M | +19.28% |
| Q1 2026 | 2026-03-31 | 287.3M | 82.2M | +40.10% |
| Q4 2025 | 2025-12-31 | 285.1M | 80.1M | +39.09% |
| Q3 2025 | 2025-09-30 | 273.9M | 69.0M | +33.65% |
| Q2 2025 | 2025-06-30 | 272.7M | 71.3M | +35.43% |
| Q1 2025 | 2025-03-31 | 205.1M | 18.0M | +9.64% |
| Q4 2024 | 2024-12-31 | 204.9M | 18.0M | +9.62% |
| Q3 2024 | 2024-09-30 | 204.9M | 18.0M | +9.62% |
| Q2 2024 | 2024-06-30 | 201.4M | 136.9M | +212.55% |
| Q1 2024 | 2024-03-31 | 187.0M | 123.5M | +194.64% |
| Q4 2023 | 2023-12-31 | 187.0M | 123.8M | +195.79% |
| Q3 2023 | 2023-09-30 | 187.0M | 145.8M | +354.05% |
| Q2 2023 | 2023-06-30 | 64.4M | 23.4M | +57.08% |
| Q1 2023 | 2023-03-31 | 63.5M | 25.0M | +64.98% |
| Q4 2022 | 2022-12-31 | 63.2M | 24.7M | +64.29% |
| Q3 2022 | 2022-09-30 | 41.2M | 2.7M | +7.02% |
| Q2 2022 | 2022-06-30 | 41.0M | 2.6M | +6.85% |
| Q1 2022 | 2022-03-31 | 38.5M | 712,510 | +1.89% |
| Q4 2021 | 2021-12-31 | 38.5M | 712,510 | +1.89% |
| Q3 2021 | 2021-09-30 | 38.5M | 712,510 | +1.89% |
| Q2 2021 | 2021-06-30 | 38.4M | 27.5M | +252.37% |
| Q1 2021 | 2021-03-31 | 37.8M | — | — |
| Q4 2020 | 2020-12-31 | 37.8M | — | — |
| Q3 2020 | 2020-09-30 | 37.8M | — | — |
| Q4 2019 | 2019-12-31 | 10.9M | — | — |
Taysha Gene Therapies shares outstanding trends
Over the last five reported fiscal years, Taysha Gene Therapies's shares outstanding moved from 37.8M to 285.1M, a change of 247.3M. The latest reported quarter, Q2 2026, shows 325.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies filings at SEC.gov ↗